Traws Pharma (TRAW) Competitors $5.02 -0.31 (-5.82%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrends TRAW vs. IMRX, IMMX, ALTS, IOBT, STTK, ITRM, FBIO, CELU, PRLD, and VTVTShould you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include Immuneering (IMRX), Immix Biopharma (IMMX), Janone (ALTS), IO Biotech (IOBT), Shattuck Labs (STTK), Iterum Therapeutics (ITRM), Fortress Biotech (FBIO), Celularity (CELU), Prelude Therapeutics (PRLD), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical preparations" industry. Traws Pharma vs. Immuneering Immix Biopharma Janone IO Biotech Shattuck Labs Iterum Therapeutics Fortress Biotech Celularity Prelude Therapeutics vTv Therapeutics Traws Pharma (NASDAQ:TRAW) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, community ranking, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation. Which has better earnings and valuation, TRAW or IMRX? Traws Pharma has higher earnings, but lower revenue than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTraws Pharma$226K67.21-$18.95M-$141.56-0.04Immuneering$320K194.06-$53.47M-$1.97-1.02 Does the media prefer TRAW or IMRX? In the previous week, Immuneering had 4 more articles in the media than Traws Pharma. MarketBeat recorded 4 mentions for Immuneering and 0 mentions for Traws Pharma. Immuneering's average media sentiment score of 0.12 beat Traws Pharma's score of 0.00 indicating that Immuneering is being referred to more favorably in the news media. Company Overall Sentiment Traws Pharma Neutral Immuneering Neutral Is TRAW or IMRX more profitable? Immuneering has a net margin of 0.00% compared to Traws Pharma's net margin of -62,294.25%. Immuneering's return on equity of -79.19% beat Traws Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Traws Pharma-62,294.25% -144.95% -822.38% Immuneering N/A -79.19%-69.08% Does the MarketBeat Community believe in TRAW or IMRX? Immuneering received 29 more outperform votes than Traws Pharma when rated by MarketBeat users. CompanyUnderperformOutperformTraws PharmaN/AN/AImmuneeringOutperform Votes2964.44% Underperform Votes1635.56% Which has more volatility and risk, TRAW or IMRX? Traws Pharma has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Immuneering has a beta of -0.33, indicating that its share price is 133% less volatile than the S&P 500. Do analysts prefer TRAW or IMRX? Immuneering has a consensus price target of $12.80, indicating a potential upside of 540.00%. Given Immuneering's stronger consensus rating and higher possible upside, analysts clearly believe Immuneering is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Immuneering 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38 Do insiders and institutionals hold more shares of TRAW or IMRX? 7.9% of Traws Pharma shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 16.1% of Traws Pharma shares are held by insiders. Comparatively, 25.0% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryImmuneering beats Traws Pharma on 14 of the 17 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRAW vs. The Competition Export to ExcelMetricTraws PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.19M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.0410.5990.1317.19Price / Sales67.21196.061,116.25117.01Price / CashN/A57.1643.1037.85Price / Book0.405.094.784.78Net Income-$18.95M$151.83M$120.31M$225.60M7 Day Performance7.95%-2.14%-1.92%-1.23%1 Month Performance12.56%-4.56%13.65%0.46%1 Year PerformanceN/A8.87%28.34%15.24% Traws Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRAWTraws PharmaN/A$5.02-5.8%N/AN/A$15.19M$226,000.00-0.0417Positive NewsGap UpHigh Trading VolumeIMRXImmuneering3.4154 of 5 stars$1.73+5.8%$12.80+639.9%-71.3%$53.72M$320,000.00-0.8360News CoverageIMMXImmix Biopharma2.8759 of 5 stars$1.95-4.4%$7.00+259.0%-69.6%$53.64MN/A-2.479News CoverageALTSJanoneN/A$3.77-3.8%N/AN/A$53.04M$7.11M0.00170Gap UpIOBTIO Biotech3.2871 of 5 stars$0.79-2.5%$9.33+1,081.4%-47.2%$52.05MN/A-0.5930News CoveragePositive NewsSTTKShattuck Labs2.6671 of 5 stars$1.09-4.4%$8.67+695.1%-82.2%$52.04M$1.66M-0.75100ITRMIterum Therapeutics2.0436 of 5 stars$1.87+3.9%$5.00+167.4%+9.3%$51.46MN/A-0.9410FBIOFortress Biotech3.342 of 5 stars$1.85-4.6%$13.67+638.7%-32.0%$51.07M$62.50M-0.63186CELUCelularity0.2712 of 5 stars$2.31+4.1%N/A+28.7%$50.79M$48.20M0.00220PRLDPrelude Therapeutics2.932 of 5 stars$0.90+12.0%$4.00+346.6%-68.0%$49.29MN/A-0.52120News CoveragePositive NewsGap UpHigh Trading VolumeVTVTvTv Therapeutics2.0082 of 5 stars$15.44+2.7%$35.00+126.7%+69.8%$49.25M$2.02M-3.329Gap Up Related Companies and Tools Related Companies Immuneering Competitors Immix Biopharma Competitors Janone Competitors IO Biotech Competitors Shattuck Labs Competitors Iterum Therapeutics Competitors Fortress Biotech Competitors Celularity Competitors Prelude Therapeutics Competitors vTv Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRAW) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRAW Stock Alerts